Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $936.18M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.47M
Average 0.31M
SLN Operating Cash Flow
Cash generated by the company's core business operations during the period.
Silence Therapeutics plcNASDAQ: SLN
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows 26.8% year over year
Q1 FY2026 operating cash flow of $15.6M (cash outflow) rose 26.8% year over year. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.
Context
- Operating cash flow amounted to 11139.7% of revenue in FY2025, up 11014.8 pp from a year earlier.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
Mixed currencies · from the cash flow
- Latest · FY2025
- (62.27M) USD
- Year-over-year change
- —
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (62.27M) | — |
| FY2024 | 2024-12-31 | (54.05M) | -37.4% |
| FY2023 | 2023-12-31 | (39.35M) | +31.0% |
| FY2022 | 2022-12-31 | (57.04M) | -721.0% |
| FY2021 | 2021-12-31 | 9.19M | — |
Operating Cash Flow vs competitors
How SLN compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Operating cash flow amounts to 7115.1% of revenue for SLN, versus a peer median of 129.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $544.41M USD | +120.4% | -0.7% | 56.7% | |
| LTM Sep 2026 | $271.95M USD | -251.5% | +20.9% | 60.3% | |
| LTM Mar 2026 | $182.35M USD | +1.0% | +13.6% | 254.0% | |
| LTM Mar 2026 | $175.28M USD | +132.0% | -14.2% | 8.0% | |
| LTM Mar 2026 | $65.57M USD | — | +3.0% | 7115.1% | |
| LTM Mar 2026 | $58.57M USD | -34.4% | — | 129.2% | |
| LTM Mar 2026 | €48.04M EUR | +29.6% | -9.5% | 357.4% | |
| FY2025 | $41.13M USD | — | — | 220.9% | |
| LTM Mar 2026 | $20.57M USD | +10.2% | +14.1% | — | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding SLN) | — | +10.2% | +6.5% | 129.2% | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (61.89M) | (50.33M) | (50.31M) | (28.92M) | (88.61M) |
| Depreciation & Amortization | 576.29K | 596K | 498K | 473.86K | 555K |
| Deferred Income Tax | 5.95M | 688K | 0 | 675.23K | 11K |
| Stock-Based Compensation | 11.65M | 12.69M | 13.05M | 10.41M | 8.07M |
| Change in Working Capital | 52.43M | (19.4M) | (11.66M) | (26.39M) | 10.16M |
| Accounts Receivables | 37.09M | (10.54M) | 314K | (722.38K) | 5.07M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.33M | (8.85M) | (11.98M) | (25.67M) | 5.09M |
| Other Non-Cash Items | 468.32K | (1.28M) | 9.07M | (10.3M) | 7.54M |
| Operating Cash Flow | 9.19M | (57.04M) | (39.35M) | (54.05M) | (62.27M) |
| Capital Expenditures | (1.8M) | (545K) | (45K) | (168.61K) | (55K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (19.95M) | (20.67M) | (111.21M) | (166.41M) |
| Sales of Investments | 13.5M | 0 | 36.18M | 0 | 118.48M |
| Other Investing Activities | (17.55K) | (372K) | 958K | 93.82M | 0 |
| Investing Cash Flow | 11.71M | (20.5M) | 16.43M | (17.55M) | (47.99M) |
| Debt Repayment | (284.77K) | 0 | (174K) | 0 | 0 |
| Common Stock Issued | 41.73M | 52.58M | 25.33M | 113.54M | 15K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.45M | 52.58M | 25.16M | 113.54M | 15K |
| Effect of Forex Changes | (141.71K) | (8.12M) | (3.02M) | 47.95K | 195K |
| Net Change in Cash | 62.2M | (33.08M) | (785K) | 41.98M | (110.05M) |
| Free Cash Flow | 7.39M | (57.59M) | (39.4M) | (54.22M) | (62.33M) |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.